Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
Mv6Z9TNAEjK9cAFU
Listen
